Suchergebnisse - "Laura Brandt"

PubPharm (17)

1

Regulatory Considerations Toward Orphan Drug Designation and Orphan Drug Exclusivity in the United States and European Union : Structural Similarity, Clinical Superiority/Significant Benefit, and Case Studies

enthalten in: Therapeutic innovation & regulatory science | 2023

von Roberts, S. | Elvang, T. | Syed, L. | +9

ErratumIn: Ther Innov Regul Sci. 2022 Dec 6;:. - PMID 36472778

2

Correction : Regulatory Considerations Toward Orphan Drug Designation and Orphan Drug Exclusivity in the United States and European Union: Structural Similarity, Clinical Superiority/Significant Benefit, and Case Studies

enthalten in: Therapeutic innovation & regulatory science | 2023

von Roberts, S. | Elvang, T. | Syed, L. | +9

ErratumFor: Ther Innov Regul Sci. 2023 Mar;57(2):386-395. - PMID 36401076

3

Capturing drug use patterns at a glance: An n-ary word sufficient statistic for repeated univariate categorical values.

in: PLoS ONE | 2023

von Gabriel J Odom | Laura Brandt | Clinton Castro | +4

4

Correction: Regulatory Considerations Toward Orphan Drug Designation and Orphan Drug Exclusivity in the United States and European Union: Structural Similarity, Clinical Superiority/Significant Benefit, and Case Studies

enthalten in: Therapeutic innovation & regulatory science | 2022

von Roberts, S. | Elvang, T. | Syed, L. | +9

5

Correction: Regulatory Considerations Toward Orphan Drug Designation and Orphan Drug Exclusivity in the United States and European Union: Structural Similarity, Clinical Superiority/Significant Benefit, and Case Studies

enthalten in: Therapeutic innovation & regulatory science | 2022

von Roberts, S. | Elvang, T. | Syed, L. | +9

6

Correction: Regulatory Considerations Toward Orphan Drug Designation and Orphan Drug Exclusivity in the United States and European Union: Structural Similarity, Clinical Superiority/Significant Benefit, and Case Studies

enthalten in: Therapeutic innovation & regulatory science | 2022

von Roberts, S. | Elvang, T. | Syed, L. | +9

7

Regulatory Considerations Toward Orphan Drug Designation and Orphan Drug Exclusivity in the United States and European Union: Structural Similarity, Clinical Superiority/Significant Benefit, and Case Studies

enthalten in: Therapeutic innovation & regulatory science | 2022

von Roberts, S. | Elvang, T. | Syed, L. | +9

8

Regulatory Considerations Toward Orphan Drug Designation and Orphan Drug Exclusivity in the United States and European Union: Structural Similarity, Clinical Superiority/Significant Benefit, and Case Studies

enthalten in: Therapeutic innovation & regulatory science | 2022

von Roberts, S. | Elvang, T. | Syed, L. | +9

9

Regulatory Considerations Toward Orphan Drug Designation and Orphan Drug Exclusivity in the United States and European Union: Structural Similarity, Clinical Superiority/Significant Benefit, and Case Studies

enthalten in: Therapeutic innovation & regulatory science | 2022

von Roberts, S. | Elvang, T. | Syed, L. | +9

10

Specific polysubstance use patterns predict relapse among patients entering opioid use disorder treatment

in: Drug and Alcohol Dependence Reports | 2022

von Yue Pan | Daniel J. Feaster | Gabriel Odom | +7